LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Kodu・Aktsiate loetelu・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Suletud

SektorTervishoid

656.79 1.56

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

649.47

Max

657.91

Põhinäitajad
By Trading Economics
Sissetulek	68M 1.5B
Müük	79M 3.8B
P/E Sektori keskmine	15.383 77.256
Dividenditootlus	0.41
Kasumimarginaal	38.889
Töötajad	15,222
EBITDA	262M 1.9B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+16.55% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	0.41% 2.33%

Turustatistika
By TradingEconomics
Turukapital	5.5B 68B
Eelmine avamishind	655.23
Eelmine sulgemishind	656.79

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

542.44 / 599.76 Toetus ja vastupanu

Regeneron Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. aug 2025, 11:33 UTC

Tulu

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

1. aug 2025, 13:16 UTC

Tulu

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1. aug 2025, 12:40 UTC

Tulu

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1. aug 2025, 10:41 UTC

Tulu

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

1. aug 2025, 10:41 UTC

Tulu

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

1. aug 2025, 10:40 UTC

Tulu

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

1. aug 2025, 10:38 UTC

Tulu

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

1. aug 2025, 10:37 UTC

Tulu

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

1. aug 2025, 10:35 UTC

Tulu

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

1. aug 2025, 10:34 UTC

Tulu

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

1. aug 2025, 10:33 UTC

Tulu

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

1. aug 2025, 10:32 UTC

Tulu

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

1. aug 2025, 10:31 UTC

Tulu

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

1. aug 2025, 10:31 UTC

Tulu

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

1. aug 2025, 10:30 UTC

Tulu

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

1. aug 2025, 10:30 UTC

Tulu

Regeneron Pharma 2Q Rev $3.68B >REGN

1. aug 2025, 10:30 UTC

Tulu

Regeneron Pharma 2Q EPS $12.81 >REGN

1. aug 2025, 10:30 UTC

Tulu

Regeneron Pharma 2Q Net $1.39B >REGN

13. juuni 2025, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13. juuni 2025, 20:45 UTC

Omandamised, ülevõtmised, äriostud

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13. juuni 2025, 20:34 UTC

Omandamised, ülevõtmised, äriostud

Anne Wojcicki Wins Bidding for 23andMe -- Update

13. juuni 2025, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13. juuni 2025, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13. juuni 2025, 20:14 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

5. juuni 2025, 01:41 UTC

Omandamised, ülevõtmised, äriostud

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30. mai 2025, 08:58 UTC

Kuumad aktsiad

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30. mai 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

19. mai 2025, 17:52 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19. mai 2025, 16:13 UTC

Omandamised, ülevõtmised, äriostud

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19. mai 2025, 14:42 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

Võrdlus sarnastega

Hinnamuutus

Regeneron Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

16.55% tõus

12 kuu keskmine prognoos

Keskmine 753.95 USD 16.55%

Kõrge 890 USD

Madal 615 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Regeneron Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

22 ratings

Osta

Hoia

Müü

Põhineb 22 analüütiku instrumendi Regeneron Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

542.44 / 599.76Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.